| __timestamp | Halozyme Therapeutics, Inc. | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 4167274 |
| Thursday, January 1, 2015 | 29245000 | 5247851 |
| Friday, January 1, 2016 | 33206000 | 4925118 |
| Sunday, January 1, 2017 | 31152000 | 14930297 |
| Monday, January 1, 2018 | 10136000 | 25371768 |
| Tuesday, January 1, 2019 | 45546000 | 23921274 |
| Wednesday, January 1, 2020 | 43367000 | 25338236 |
| Friday, January 1, 2021 | 81413000 | 20182966 |
| Saturday, January 1, 2022 | 139304000 | 17562000 |
| Sunday, January 1, 2023 | 192361000 | 25212000 |
Infusing magic into the data realm
In the ever-evolving biotech industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Halozyme Therapeutics, Inc. and Pharming Group N.V. from 2014 to 2023. Over this period, Halozyme's cost of revenue surged by an impressive 747%, peaking in 2023. This growth reflects the company's expanding operations and increased production costs. In contrast, Pharming Group N.V. experienced a more modest increase of 505%, with a notable spike in 2018. This divergence highlights different strategic approaches: Halozyme's aggressive expansion versus Pharming's steady growth. The data underscores the importance of cost management in maintaining competitive advantage in the biotech sector. As these companies continue to innovate, monitoring their cost of revenue will provide valuable insights into their financial health and strategic direction.
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Pharming Group N.V.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Incyte Corporation and Pharming Group N.V.'s Expenses
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Jazz Pharmaceuticals plc and Halozyme Therapeutics, Inc.'s Expenses
Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs Wave Life Sciences Ltd.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Viridian Therapeutics, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Pharming Group N.V. vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Pharming Group N.V. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Pharming Group N.V. and Galapagos NV's Expenses
Cost of Revenue Trends: Pharming Group N.V. vs Evotec SE